The impact of SARS‑CoV‑2 treatment on the cardiovascular system : an updated review

Mohammed Ahmed, Akkaif and Abubakar, Sha’aban and Arturo, Cesaro and Ammar Ali, Saleh Jaber and Andrea, Vergara and Ismaeel, Yunusa and Abubakar Ibrahim, Jatau and Mustapha, Mohammed and G. Saravana, Govindasamy and Majed Ahmed, Al-Mansoub and Muhamad Ali Sheikh, Abdul Kader and Baharudin, Ibrahim (2022) The impact of SARS‑CoV‑2 treatment on the cardiovascular system : an updated review. Infammopharmacology, 30. pp. 1143-1151. ISSN 1568-5608

PDF s10787-022-01009-8.pdf Download (1MB)

Abstract

The coronavirus disease-2019 (COVID-19) pandemic has become a major global health problem. COVID-19 is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and exhibits pulmonary and extrapulmonary efects, including cardiovascular involvement. There are several attempts to identify drugs that could treat COVID-19. Moreover, many patients infected with COVID-19 have underlying diseases, particularly cardiovascular diseases. These patients are more likely to develop severe illnesses and would require optimized treatment strategies. The current study gathered information from various databases, including relevant studies, reviews, trials, or meta-analyses until April 2022 to identify the impact of SARS-CoV-2 treatment on the cardiovascular system. Studies have shown that the prognosis of patients with underlying cardiovascular disease is worsened by COVID-19, with some COVID-19 medications interfering with the cardiovascular system. The COVID-19 treatment strategy should consider many factors and parameters to avoid medication-induced cardiac injury, mainly in elderly patients. Therefore, this article provides a synthesis of evidence on the impact of diferent COVID19 medications on the cardiovascular system and related disease conditions.

Actions (For repository members only: login required)

View Item